疗效与安全性-话题@MedSci

#疗效与安全性#

24篇内容 | 1837人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2171461, encodeId=b58821e1461b9, content=<a href='/topic/show?id=c0ae9405422' target=_blank style='color:#2F92EE;'>#过敏性鼻炎#</a> <a href='/topic/show?id=d661e039969' target=_blank style='color:#2F92EE;'>#疗效与安全性#</a> <a href='/topic/show?id=811010e951fd' target=_blank style='color:#2F92EE;'>#盐酸氮卓斯汀#</a>, objectTitle=Front Allergy：盐酸氮卓斯汀对常年性过敏性鼻炎疗效和安全性分析：一项双盲安慰剂对照试验 , objectType=article, longId=802721, objectId=e3dd802e21d0, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20231128/1701143858606_1935437.jpg, objectUrl=/article/show_article.do?id=e3dd802e21d0, replyNumber=0, likeNumber=81, createdTime=2023-11-28, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=e3dd802e21d0, moduleTitle=Front Allergy：盐酸氮卓斯汀对常年性过敏性鼻炎疗效和安全性分析：一项双盲安慰剂对照试验 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e3dd802e21d0)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1688638, encodeId=7b4e1688638bb, content=<a href='/topic/show?id=d661e039969' target=_blank style='color:#2F92EE;'>#疗效与安全性#</a>, objectTitle=Dermatol Ther：体外光疗治疗系统性硬化症的疗效与安全性, objectType=article, longId=733075, objectId=612de3307549, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=612de3307549, replyNumber=0, likeNumber=104, createdTime=2022-10-05, rootId=0, userName=1179102698_36768935, userId=1a6a28606469, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=612de3307549, moduleTitle=Dermatol Ther：体外光疗治疗系统性硬化症的疗效与安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=612de3307549)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1688636, encodeId=46f81688636a7, content=<a href='/topic/show?id=d661e039969' target=_blank style='color:#2F92EE;'>#疗效与安全性#</a>, objectTitle=J Crohns Colitis：维多珠单抗治疗溃疡性结肠炎或克罗恩病小儿患者的疗效与安全性, objectType=article, longId=301445, objectId=17463014452e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=17463014452e, replyNumber=0, likeNumber=93, createdTime=2022-12-11, rootId=0, userName=1179102698_36768935, userId=1a6a28606469, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=17463014452e, moduleTitle=J Crohns Colitis：维多珠单抗治疗溃疡性结肠炎或克罗恩病小儿患者的疗效与安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=17463014452e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1688637, encodeId=0bff168863e0b, content=<a href='/topic/show?id=d661e039969' target=_blank style='color:#2F92EE;'>#疗效与安全性#</a>, objectTitle=2022 ASCO：RP1+nivo治疗皮肤癌的疗效与安全性——IGNYTE研究的最新结果, objectType=article, longId=728230, objectId=1cdae2823048, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1cdae2823048, replyNumber=0, likeNumber=107, createdTime=2023-04-27, rootId=0, userName=1179102698_36768935, userId=1a6a28606469, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1cdae2823048, moduleTitle=2022 ASCO：RP1+nivo治疗皮肤癌的疗效与安全性——IGNYTE研究的最新结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1cdae2823048)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1688633, encodeId=179e168863362, content=<a href='/topic/show?id=d661e039969' target=_blank style='color:#2F92EE;'>#疗效与安全性#</a>, objectTitle=JCEM：Tildacerfont对成人典型先天性肾上腺增生症患者的疗效与安全性研究, objectType=article, longId=215877, objectId=e4672158e7b5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e4672158e7b5, replyNumber=0, likeNumber=64, createdTime=2021-10-26, rootId=0, userName=1179102698_36768935, userId=1a6a28606469, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e4672158e7b5, moduleTitle=JCEM：Tildacerfont对成人典型先天性肾上腺增生症患者的疗效与安全性研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e4672158e7b5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1688635, encodeId=256216886351b, content=<a href='/topic/show?id=d661e039969' target=_blank style='color:#2F92EE;'>#疗效与安全性#</a>, objectTitle=吉西他滨与奥沙利铂联合对复发、耐药老年淋巴瘤患者的疗效与安全性分析, objectType=article, longId=220684, objectId=5d632206847f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5d632206847f, replyNumber=0, likeNumber=74, createdTime=2021-12-04, rootId=0, userName=1179102698_36768935, userId=1a6a28606469, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5d632206847f, moduleTitle=吉西他滨与奥沙利铂联合对复发、耐药老年淋巴瘤患者的疗效与安全性分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5d632206847f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1688634, encodeId=9113168863420, content=<a href='/topic/show?id=d661e039969' target=_blank style='color:#2F92EE;'>#疗效与安全性#</a>, objectTitle=NEJM：曲妥珠ADC T-DXd用于HER2过表达的NSCLC的疗效与安全性（DESTINY-Lung01研究）, objectType=article, longId=217405, objectId=0fe821e405f8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0fe821e405f8, replyNumber=0, likeNumber=0, createdTime=2022-07-29, rootId=0, userName=1179102698_36768935, userId=1a6a28606469, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0fe821e405f8, moduleTitle=NEJM：曲妥珠ADC T-DXd用于HER2过表达的NSCLC的疗效与安全性（DESTINY-Lung01研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0fe821e405f8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1688632, encodeId=bad01688632ab, content=<a href='/topic/show?id=d661e039969' target=_blank style='color:#2F92EE;'>#疗效与安全性#</a>, objectTitle=J Hematol Oncol：PD-1单抗---杰诺单抗注射液(geptanolimab）对外周T细胞淋巴瘤(PTCL) 的疗效与安全性, objectType=article, longId=214110, objectId=d47e2141105c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d47e2141105c, replyNumber=0, likeNumber=85, createdTime=2022-04-08, rootId=0, userName=1179102698_36768935, userId=1a6a28606469, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d47e2141105c, moduleTitle=J Hematol Oncol：PD-1单抗---杰诺单抗注射液(geptanolimab）对外周T细胞淋巴瘤(PTCL) 的疗效与安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d47e2141105c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1688631, encodeId=0b271688631e8, content=<a href='/topic/show?id=d661e039969' target=_blank style='color:#2F92EE;'>#疗效与安全性#</a>, objectTitle=J Immunother Cancer：PD1抑制剂联合ipilimumab在伴有自身免疫疾病晚期黑素色瘤患者的疗效与安全性, objectType=article, longId=211247, objectId=676f21124ed8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=676f21124ed8, replyNumber=0, likeNumber=86, createdTime=2021-11-01, rootId=0, userName=1179102698_36768935, userId=1a6a28606469, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=676f21124ed8, moduleTitle=J Immunother Cancer：PD1抑制剂联合ipilimumab在伴有自身免疫疾病晚期黑素色瘤患者的疗效与安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=676f21124ed8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1688628, encodeId=c73916886288d, content=<a href='/topic/show?id=d661e039969' target=_blank style='color:#2F92EE;'>#疗效与安全性#</a>, objectTitle=Medicine：托西利珠单抗用于秋水仙碱无效或不耐受的家族性地中海热的疗效与安全性研究, objectType=article, longId=198094, objectId=69af1980945f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=69af1980945f, replyNumber=0, likeNumber=100, createdTime=2020-10-17, rootId=0, userName=1179102698_36768935, userId=1a6a28606469, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=69af1980945f, moduleTitle=Medicine：托西利珠单抗用于秋水仙碱无效或不耐受的家族性地中海热的疗效与安全性研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=69af1980945f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1688630, encodeId=ef9a1688630d1, content=<a href='/topic/show?id=d661e039969' target=_blank style='color:#2F92EE;'>#疗效与安全性#</a>, objectTitle=Annals of Oncology：T-DM1在HER2阳性转移性乳腺癌和脑转移乳腺癌患者中的疗效与安全性, objectType=article, longId=199369, objectId=112e19936941, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=112e19936941, replyNumber=0, likeNumber=90, createdTime=2021-02-06, rootId=0, userName=1179102698_36768935, userId=1a6a28606469, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=112e19936941, moduleTitle=Annals of Oncology：T-DM1在HER2阳性转移性乳腺癌和脑转移乳腺癌患者中的疗效与安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=112e19936941)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1688629, encodeId=bf051688629c7, content=<a href='/topic/show?id=d661e039969' target=_blank style='color:#2F92EE;'>#疗效与安全性#</a>, objectTitle=EUR HEART J-CARD PHA：依多沙班与华法林对房颤患者疾病负担的疗效与安全性？ , objectType=article, longId=198585, objectId=cb3419858558, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cb3419858558, replyNumber=0, likeNumber=88, createdTime=2021-01-07, rootId=0, userName=1179102698_36768935, userId=1a6a28606469, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cb3419858558, moduleTitle=EUR HEART J-CARD PHA：依多沙班与华法林对房颤患者疾病负担的疗效与安全性？ , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cb3419858558)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1688627, encodeId=1a97168862eb9, content=<a href='/topic/show?id=d661e039969' target=_blank style='color:#2F92EE;'>#疗效与安全性#</a>, objectTitle=NEJM：Tepotinib在NSCLC中的MET Exon 14跳跃突变中的疗效与安全性, objectType=article, longId=195765, objectId=05d3195e65a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=05d3195e65a2, replyNumber=0, likeNumber=99, createdTime=2020-12-24, rootId=0, userName=1179102698_36768935, userId=1a6a28606469, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=05d3195e65a2, moduleTitle=NEJM：Tepotinib在NSCLC中的MET Exon 14跳跃突变中的疗效与安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=05d3195e65a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1688623, encodeId=cb92168862355, content=<a href='/topic/show?id=d661e039969' target=_blank style='color:#2F92EE;'>#疗效与安全性#</a>, objectTitle=李志铭教授：疗效与安全性双赢--新型BTK抑制剂Zanubrutinib为B细胞淋巴瘤患者带来治疗新选择, objectType=article, longId=157138, objectId=55df15e138c5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=55df15e138c5, replyNumber=0, likeNumber=74, createdTime=2019-11-14, rootId=0, userName=1179102698_36768935, userId=1a6a28606469, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=55df15e138c5, moduleTitle=李志铭教授：疗效与安全性双赢--新型BTK抑制剂Zanubrutinib为B细胞淋巴瘤患者带来治疗新选择, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=55df15e138c5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1688625, encodeId=08bd168862525, content=<a href='/topic/show?id=d661e039969' target=_blank style='color:#2F92EE;'>#疗效与安全性#</a>, objectTitle=FTD（TAS-102）后线治疗晚期胃癌疗效与安全性并优, objectType=article, longId=168155, objectId=2445168155ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2445168155ce, replyNumber=0, likeNumber=67, createdTime=2019-07-30, rootId=0, userName=1179102698_36768935, userId=1a6a28606469, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2445168155ce, moduleTitle=FTD（TAS-102）后线治疗晚期胃癌疗效与安全性并优, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2445168155ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1688624, encodeId=3b201688624af, content=<a href='/topic/show?id=d661e039969' target=_blank style='color:#2F92EE;'>#疗效与安全性#</a>, objectTitle=氟马替尼治疗CML-CP的疗效与安全性解读, objectType=article, longId=167915, objectId=68f016e91570, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=68f016e91570, replyNumber=0, likeNumber=82, createdTime=2019-09-15, rootId=0, userName=1179102698_36768935, userId=1a6a28606469, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=68f016e91570, moduleTitle=氟马替尼治疗CML-CP的疗效与安全性解读, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=68f016e91570)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1688626, encodeId=5a761688626e1, content=<a href='/topic/show?id=d661e039969' target=_blank style='color:#2F92EE;'>#疗效与安全性#</a>, objectTitle=腺癌治疗所致骨丢失的治疗研究：无论是否联合运动，大剂量维生素D的疗效与安全性均优, objectType=article, longId=168216, objectId=9cf41682169e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9cf41682169e, replyNumber=0, likeNumber=77, createdTime=2019-08-03, rootId=0, userName=1179102698_36768935, userId=1a6a28606469, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9cf41682169e, moduleTitle=腺癌治疗所致骨丢失的治疗研究：无论是否联合运动，大剂量维生素D的疗效与安全性均优, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9cf41682169e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1688622, encodeId=751e1688622fa, content=<a href='/topic/show?id=d661e039969' target=_blank style='color:#2F92EE;'>#疗效与安全性#</a>, objectTitle=诺华Cosentyx(R)5年III期数据展现出持久疗效与安全性, objectType=article, longId=112819, objectId=a992112819c5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a992112819c5, replyNumber=0, likeNumber=87, createdTime=2018-01-06, rootId=0, userName=爆笑小医, userId=395f25, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a992112819c5, moduleTitle=诺华Cosentyx(R)5年III期数据展现出持久疗效与安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a992112819c5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1688621, encodeId=a1f116886217d, content=<a href='/topic/show?id=d661e039969' target=_blank style='color:#2F92EE;'>#疗效与安全性#</a>, objectTitle=ESC 2017：韩雅玲院士：我国自主研发的生物可降解支架疗效与安全性好, objectType=article, longId=111544, objectId=d0821115443d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d0821115443d, replyNumber=0, likeNumber=94, createdTime=2017-10-19, rootId=0, userName=1179102698_36768935, userId=1a6a28606469, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d0821115443d, moduleTitle=ESC 2017：韩雅玲院士：我国自主研发的生物可降解支架疗效与安全性好, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d0821115443d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1688620, encodeId=a531168862037, content=<a href='/topic/show?id=d661e039969' target=_blank style='color:#2F92EE;'>#疗效与安全性#</a>, objectTitle=Hypertension：基因治疗对高血压和急性肾损伤的疗效与安全性, objectType=article, longId=105979, objectId=cb441059e99a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cb441059e99a, replyNumber=0, likeNumber=72, createdTime=2018-02-12, rootId=0, userName=1179102698_36768935, userId=1a6a28606469, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cb441059e99a, moduleTitle=Hypertension：基因治疗对高血压和急性肾损伤的疗效与安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cb441059e99a)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

疗效与安全性

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#过敏性鼻炎# #疗效与安全性# #盐酸氮卓斯汀#

Front Allergy：盐酸氮卓斯汀对常年性过敏性鼻炎疗效和安全性分析：一项双盲安慰剂对照试验

2023-11-28发表于上海

1179102698_36768935 (审核中...)

前往app查看评论内容

#疗效与安全性#

Dermatol Ther：体外光疗治疗系统性硬化症的疗效与安全性

2022-10-05

1179102698_36768935 (审核中...)

前往app查看评论内容

#疗效与安全性#

J Crohns Colitis：维多珠单抗治疗溃疡性结肠炎或克罗恩病小儿患者的疗效与安全性

2022-12-11

1179102698_36768935 (审核中...)

前往app查看评论内容

#疗效与安全性#

2022 ASCO：RP1+nivo治疗皮肤癌的疗效与安全性——IGNYTE研究的最新结果

2023-04-27

1179102698_36768935 (审核中...)

前往app查看评论内容

#疗效与安全性#

JCEM：Tildacerfont对成人典型先天性肾上腺增生症患者的疗效与安全性研究

2021-10-26

1179102698_36768935 (审核中...)

前往app查看评论内容

#疗效与安全性#

吉西他滨与奥沙利铂联合对复发、耐药老年淋巴瘤患者的疗效与安全性分析

2021-12-04

1179102698_36768935 (审核中...)

前往app查看评论内容

#疗效与安全性#

NEJM：曲妥珠ADC T-DXd用于HER2过表达的NSCLC的疗效与安全性（DESTINY-Lung01研究）

2022-07-29

1179102698_36768935 (审核中...)

前往app查看评论内容

#疗效与安全性#

J Hematol Oncol：PD-1单抗---杰诺单抗注射液(geptanolimab）对外周T细胞淋巴瘤(PTCL) 的疗效与安全性

2022-04-08

1179102698_36768935 (审核中...)

前往app查看评论内容

#疗效与安全性#

J Immunother Cancer：PD1抑制剂联合ipilimumab在伴有自身免疫疾病晚期黑素色瘤患者的疗效与安全性

2021-11-01

1179102698_36768935 (审核中...)

前往app查看评论内容

#疗效与安全性#

Medicine：托西利珠单抗用于秋水仙碱无效或不耐受的家族性地中海热的疗效与安全性研究

2020-10-17

1179102698_36768935 (审核中...)

前往app查看评论内容

#疗效与安全性#

Annals of Oncology：T-DM1在HER2阳性转移性乳腺癌和脑转移乳腺癌患者中的疗效与安全性

2021-02-06

1179102698_36768935 (审核中...)

前往app查看评论内容

#疗效与安全性#

EUR HEART J-CARD PHA：依多沙班与华法林对房颤患者疾病负担的疗效与安全性？

2021-01-07

1179102698_36768935 (审核中...)

前往app查看评论内容

#疗效与安全性#

NEJM：Tepotinib在NSCLC中的MET Exon 14跳跃突变中的疗效与安全性

2020-12-24

1179102698_36768935 (审核中...)

前往app查看评论内容

#疗效与安全性#

李志铭教授：疗效与安全性双赢--新型BTK抑制剂Zanubrutinib为B细胞淋巴瘤患者带来治疗新选择

2019-11-14

1179102698_36768935 (审核中...)

前往app查看评论内容

#疗效与安全性#

FTD（TAS-102）后线治疗晚期胃癌疗效与安全性并优

2019-07-30

1179102698_36768935 (审核中...)

前往app查看评论内容

#疗效与安全性#

氟马替尼治疗CML-CP的疗效与安全性解读

2019-09-15

1179102698_36768935 (审核中...)

前往app查看评论内容

#疗效与安全性#

腺癌治疗所致骨丢失的治疗研究：无论是否联合运动，大剂量维生素D的疗效与安全性均优

2019-08-03

爆笑小医 (审核中...)

前往app查看评论内容

#疗效与安全性#

诺华Cosentyx(R)5年III期数据展现出持久疗效与安全性

2018-01-06

1179102698_36768935 (审核中...)

前往app查看评论内容

#疗效与安全性#

ESC 2017：韩雅玲院士：我国自主研发的生物可降解支架疗效与安全性好

2017-10-19

1179102698_36768935 (审核中...)

前往app查看评论内容

#疗效与安全性#

Hypertension：基因治疗对高血压和急性肾损伤的疗效与安全性

2018-02-12

科室
- - 订阅+
  - 更多科室
工具
服务